Al­to Neu­ro­science un­veils ef­fi­ca­cy sig­nal from PhI­Ia MDD tri­al with ma­chine learn­ing-iden­ti­fied bio­mark­er

Al­to Neu­ro­science has un­veiled topline da­ta from a mid-stage tri­al of its ma­jor de­pres­sive dis­or­der (MDD) drug can­di­date, which showed po­ten­tial in pa­tients with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER